mathom/ct_dataset huggingface dataset:
Trial Id: The Effect of Breast Cancer Screening Training Recruitment Status: Active, not recruiting Trail description: The lack of knowledge of women on breast cancer and health literacy poses a major obstacle to people's breast cancer screening behaviors and beliefs. In order to increase social sensitivity and awareness on this issue; In particular, it is important to research, examine and examine how the municipalities and their employees, who are representatives of the society, evaluate breast cancer screening studies. The aim of our project is to evaluate the effect of breast cancer screening training given to women working in the municipality on health literacy, breast cancer screening belief and behavior. This study will be conducted in a randomized-controlled experimental design with women (n=120) working in a municipality in Istanbul Province between November 2022 and November 2023. Data will be obtained face-to-face using the Participant Information Form, the Health Literacy Scale and the Breast Cancer Screening Beliefs Scale. The women in the experimental group (n=60) will be given 16 hours of breast cancer screening training, two days a week, two hours a day (60 min+60 min) for four weeks, by the researchers. No application will be made to the control group (n=60). Follow-up evaluations of the research will be completed in the following six months. The Health Literacy Scale and Breast Cancer Screening Beliefs Scale will be re-administered to all women in the experimental and control groups at the first follow-up after three months and at the second follow-up after 6 months. The data will be analyzed with statistical methods and the effectiveness of the training will be evaluated.

When the project is concluded; The results will be presented as an article in a national or international journal, or as an oral presentation at a national or international congress. It will be ensured that breast cancer screening training given to women working in the municipality will increase their level of health literacy, have a positive effect on breast cancer screening belief and behavior, and increase their awareness and knowledge level on this subject. In the long term, widespread effects such as reducing the costs women spend on breast cancer, reducing mortality and morbidity rates, raising a conscious society, training undergraduate students involved in the project, and helping them learn by experiencing the research conducted at the national level are foreseen. Inclusion Criteria: Women aged 18 and over,
Volunteering to participate in the study,
Working in the municipality for at least 1 month and
Not having any communication problems Exclusion Criteria: Women who have any communication barrier and
Do not volunteer to participate in the study will be excluded from the study.
Provide description for trial id: NCT05723237  
 The lack of knowledge of women on breast cancer and health literacy poses a major obstacle to people's breast cancer screening behaviors and beliefs. In order to increase social sensitivity and awareness on this issue; In particular, it is important to research, examine and examine how the municipalities and their employees, who are representatives of the society, evaluate breast cancer screening studies. The aim of our project is to evaluate the effect of breast cancer screening training given to women working in the municipality on health literacy, breast cancer screening belief and behavior. This study will be conducted in a randomized-controlled experimental design with women (n=120) working in a municipality in Istanbul Province between November 2022 and November 2023. Data will be obtained face-to-face using the Participant Information Form, the Health Literacy Scale and the Breast Cancer Screening Beliefs Scale. The women in the experimental group (n=60) will be given 16 hours of breast cancer screening training, two days a week, two hours a day (60 min+60 min) for four weeks, by the researchers. No application will be made to the control group (n=60). Follow-up evaluations of the research will be completed in the following six months. The Health Literacy Scale and Breast Cancer Screening Beliefs Scale will be re-administered to all women in the experimental and control groups at the first follow-up after three months and at the second follow-up after 6 months. The data will be analyzed with statistical methods and the effectiveness of the training will be evaluated.

When the project is concluded; The results will be presented as an article in a national or international journal, or as an oral presentation at a national or international congress. It will be ensured that breast cancer screening training given to women working in the municipality will increase their level of health literacy, have a positive effect on breast cancer screening belief and behavior, and increase their awareness and knowledge level on this subject. In the long term, widespread effects such as reducing the costs women spend on breast cancer, reducing mortality and morbidity rates, raising a conscious society, training undergraduate students involved in the project, and helping them learn by experiencing the research conducted at the national level are foreseen.
Trial Id: Evaluation of Effectiveness of Acupuncture on Quality of Life in Patients With Breast Cancer Receiving Chemotherapy Recruitment Status: Completed Trail description: The aim of this trial is to investigate the effectiveness of acupuncture on quality of life in patients with breast cancer receiving chemotherapy compared to routine care. Inclusion Criteria: diagnosed breast cancer (invasive, intraductal, hormone-sensitive and not hormone-sensitive, only locoregional metastases)
current chemotherapy at Mammazentrum Hamburg with regimen FEC/DOC or EC/DOC
willingness to receive acupuncture within the next 6 month if randomized in acupuncture group
willingness to refrain from acupuncture within the next 6 month if randomized in control group
informed consent Exclusion Criteria: distant metastases
blood coagulation disorder and/or current use of anticoagulants
serious acute or chronic mental or physical disorders
clinically relevant cardiac arrhythmia symptoms
insufficient German language ability
Provide inclusion criteria for trial id: NCT01727362  
 diagnosed breast cancer (invasive, intraductal, hormone-sensitive and not hormone-sensitive, only locoregional metastases)
current chemotherapy at Mammazentrum Hamburg with regimen FEC/DOC or EC/DOC
willingness to receive acupuncture within the next 6 month if randomized in acupuncture group
willingness to refrain from acupuncture within the next 6 month if randomized in control group
informed consent
Trial Id: Evaluation of a Novel Infra-red Breast Imaging System for Risk Assessment in Women at High Risk for Breast Cancer. Recruitment Status: Unknown status Trail description: Three-dimensional functional Metabolic Imaging (3D MIRA) is a new infrared imaging technology using the Real Imager 4(RI4) developed by Real Imaging. This technology generates 3D metabolic maps and based on sophisticated machine learning technology, provides objective risk assessment for the presence of malignant tumor. The procedure is non-invasive, comfortable and does not involve ionizing radiation. Moreover, Real Imaging's 3D Functional MIRA is unaffected by breast density and is therefore ideal for evaluating patients with mammographically dense breasts.

The purpose of this clinical study is to assess the ability of this novel technology to detect clinically occult breast cancer in a cohort of women that are at high risk for breast cancer.

We hypothesize that the combination of screening mammography and metabolic screening (3D MIRA) will result in significantly higher breast cancer detection rates. Inclusion Criteria: Female
Woman has read, understood and signed the inform consent form
Age: 20 years and older
Women who are asymptomatic for breast cancer
Proven carriers of deleterious BRCA1 or BRCA2 mutations Or Women that were found to have a lifetime risk of developing breast cancer greater or equal to 20% based on Tyrer-Cuzick, Gail or Clause risk models
Women scheduled to undergo routine mammography and/or US or MRI screening Exclusion Criteria: Women who have had a mammography and/or ultrasound examination performed on the day of the study prior to MIRA scan
Women who had a lumpectomy surgery
Women who had undergone mastectomy and/or reconstruction
Women who have undergone any type of breast surgery throughout the 6 months preceding the study
Women who have had a breast biopsy performed throughout the 10 weeks preceding the study.
Women who have a fever on the day of the MIRA imaging
Women who are pregnant
Women who are breast-feeding
Women who had undergone breast reduction/augmentation
Provide inclusion criteria for trial id: NCT02009150  
 Female
Woman has read, understood and signed the inform consent form
Age: 20 years and older
Women who are asymptomatic for breast cancer
Proven carriers of deleterious BRCA1 or BRCA2 mutations Or Women that were found to have a lifetime risk of developing breast cancer greater or equal to 20% based on Tyrer-Cuzick, Gail or Clause risk models
Women scheduled to undergo routine mammography and/or US or MRI screening
Provide exclusion criteria for trial id: NCT02009150  
 Women who have had a mammography and/or ultrasound examination performed on the day of the study prior to MIRA scan
Women who had a lumpectomy surgery
Women who had undergone mastectomy and/or reconstruction
Women who have undergone any type of breast surgery throughout the 6 months preceding the study
Women who have had a breast biopsy performed throughout the 10 weeks preceding the study.
Women who have a fever on the day of the MIRA imaging
Women who are pregnant
Women who are breast-feeding
Women who had undergone breast reduction/augmentation
Provide description for trial id: NCT02009150  
 Three-dimensional functional Metabolic Imaging (3D MIRA) is a new infrared imaging technology using the Real Imager 4(RI4) developed by Real Imaging. This technology generates 3D metabolic maps and based on sophisticated machine learning technology, provides objective risk assessment for the presence of malignant tumor. The procedure is non-invasive, comfortable and does not involve ionizing radiation. Moreover, Real Imaging's 3D Functional MIRA is unaffected by breast density and is therefore ideal for evaluating patients with mammographically dense breasts.

The purpose of this clinical study is to assess the ability of this novel technology to detect clinically occult breast cancer in a cohort of women that are at high risk for breast cancer.

We hypothesize that the combination of screening mammography and metabolic screening (3D MIRA) will result in significantly higher breast cancer detection rates.
Trial Id: Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer Recruitment Status: Recruiting Trail description: Breast cancer patients who undergo neoadjuvant systemic therapy and have residual breast cancer identified at the time of surgery exhibit a high (>50%) risk of future life-threatening recurrences and death. Inclusion Criteria: Age ≥18 years.
Diagnosis of invasive breast cancer treated with neoadjuvant systemic therapy.
Surgically resectable disease following neoadjuvant systemic treatment.

At least one of the following must be true:

Received at least 2 weeks of neoadjuvant endocrine therapy
Received at least 2 months of neoadjuvant chemotherapy with suggestion of residual disease on imaging
Began neoadjuvant chemotherapy or endocrine therapy but discontinued due to evidence of progressive disease by MRI, ultrasound, or physical examination
Provide written informed consent.
Willing to return to enrolling institution for breast cancer surgery.
Willingness to provide mandatory blood specimens for future research on breast cancer at Mayo Clinic.
Willingness to provide mandatory tissue specimens for future research on breast cancer at Mayo Clinic.
Willingness to provide mandatory tissue specimens for the generation of PDX and organoids to be used future research on breast cancer at Mayo Clinic. Exclusion Criteria: Ineligible for surgery.
History of prior malignancy <3 years prior to registration. Exceptions for non-melanoma skin cancer, papillary thyroid cancer, non-invasive cancer (e.g., carcinoma in situ of the cervix).
Provide inclusion criteria for trial id: NCT04703244  
 Age ≥18 years.
Diagnosis of invasive breast cancer treated with neoadjuvant systemic therapy.
Surgically resectable disease following neoadjuvant systemic treatment.

At least one of the following must be true:

Received at least 2 weeks of neoadjuvant endocrine therapy
Received at least 2 months of neoadjuvant chemotherapy with suggestion of residual disease on imaging
Began neoadjuvant chemotherapy or endocrine therapy but discontinued due to evidence of progressive disease by MRI, ultrasound, or physical examination
Provide written informed consent.
Willing to return to enrolling institution for breast cancer surgery.
Willingness to provide mandatory blood specimens for future research on breast cancer at Mayo Clinic.
Willingness to provide mandatory tissue specimens for future research on breast cancer at Mayo Clinic.
Willingness to provide mandatory tissue specimens for the generation of PDX and organoids to be used future research on breast cancer at Mayo Clinic.
Trial Id: Breast Cancer Risk Reduction: A Patient Doctor Intervention Recruitment Status: Completed Trail description: The proposed research combines the scientific advances in breast cancer research with health information technology (IT) to design a personalized intervention that assesses breast cancer risk for women, disseminates important breast health information, and facilitates discussion of breast cancer risk reduction practices. Our goal is to implement a tablet-PC (personal computer) based breast cancer risk education (BreastCare) intervention in the primary care setting that estimates a woman's individual risk for breast cancer and provides her and her physician with personalized breast cancer risk information and recommendations for action. Inclusion Criteria: Patient component:

Women who visit the General Internal Medicine (GIM) practices at SFGH and UCSF during the study period
Between the ages of 40 and 74
Self-identify as Asian American, Spanish- and English-speaking Latinas, African American, or White
Have no history of breast cancer are eligible to participate.
Physician component: Primary care physicians currently practicing at the GIM clinics at SFGH and UCSF Exclusion Criteria: Patient component: Women whose physicians object to their participation in the study
Physician component: No exclusion criteria for physicians
Provide inclusion criteria for trial id: NCT01830933  
 Patient component:

Women who visit the General Internal Medicine (GIM) practices at SFGH and UCSF during the study period
Between the ages of 40 and 74
Self-identify as Asian American, Spanish- and English-speaking Latinas, African American, or White
Have no history of breast cancer are eligible to participate.
Physician component: Primary care physicians currently practicing at the GIM clinics at SFGH and UCSF
Provide description for trial id: NCT01830933  
 The proposed research combines the scientific advances in breast cancer research with health information technology (IT) to design a personalized intervention that assesses breast cancer risk for women, disseminates important breast health information, and facilitates discussion of breast cancer risk reduction practices. Our goal is to implement a tablet-PC (personal computer) based breast cancer risk education (BreastCare) intervention in the primary care setting that estimates a woman's individual risk for breast cancer and provides her and her physician with personalized breast cancer risk information and recommendations for action.
Trial Id: VEGF-targeted Fluorescent Tracer Imaging in Breast Cancer Recruitment Status: Completed Trail description: The purpose of this study is to determine the uptake, (semi-)quantification and localization of the VEGF targeting fluorescent tracer bevacizumab-IDRye800CW in breast cancer tissue, surrounding healthy tissue, tumor margins and lymph nodes. This is measured in surgical specimens after a single intravenous administration of 4,5 bevacizumab-IDRye800CW, using fluorescence microscopy and macroscopy techniques. Also the safety of bevacizumab-IDRye800CW is assessed. Another purpose is to assess the abilities of three different fluorescent signal detection systems to detect the fluorescent signal pre- and intra-operatively. Inclusion Criteria: Age ≥ 18 years.
Patients with proven breast cancer (cytology, histology) who are scheduled to receive operation intervention.
Tumor size of at least 15 mm diameter according to anatomical imaging data.
Signed written informed consent.
Able to comply with the protocol.
WHO performance score 0-2. Exclusion Criteria: Other invasive malignancy.
Serious other medical conditions.
Pregnant or lactating women. (Documentation of a negative pregnancy test must be available for pre-menopausal women with intact reproductive organs and for women less than two years after menopause).
Prior radiotherapy on the involved area.
Major surgery within 28 days before the initiation of the study.
Prior allergic reaction to immunoglobulins or immunoglobulin allergy.
Prior neo-adjuvant chemotherapy.
Breast prosthesis in target breast.

UMC Utrecht (FDOT) specific exclusion criteria

Breast is too big to fit in the biggest cup or is too small to fit in the smallest cup of the FDOT system.
Non-intact skin at time of the FDOT procedures.
Breast located skin diseases.
Piercings or tattoos located on the breast/nipple.
Contra-indication for MR procedures or claustrophobia.
Inability to lay prone positioned for the duration of the FDOT procedure (10 minutes) and MR procedure (30 minutes).
Tumor located close to the chest wall as assessed by breast imaging data.
Provide exclusion criteria for trial id: NCT01508572  
 Other invasive malignancy.
Serious other medical conditions.
Pregnant or lactating women. (Documentation of a negative pregnancy test must be available for pre-menopausal women with intact reproductive organs and for women less than two years after menopause).
Prior radiotherapy on the involved area.
Major surgery within 28 days before the initiation of the study.
Prior allergic reaction to immunoglobulins or immunoglobulin allergy.
Prior neo-adjuvant chemotherapy.
Breast prosthesis in target breast.

UMC Utrecht (FDOT) specific exclusion criteria

Breast is too big to fit in the biggest cup or is too small to fit in the smallest cup of the FDOT system.
Non-intact skin at time of the FDOT procedures.
Breast located skin diseases.
Piercings or tattoos located on the breast/nipple.
Contra-indication for MR procedures or claustrophobia.
Inability to lay prone positioned for the duration of the FDOT procedure (10 minutes) and MR procedure (30 minutes).
Tumor located close to the chest wall as assessed by breast imaging data.
Provide description for trial id: NCT01508572  
 The purpose of this study is to determine the uptake, (semi-)quantification and localization of the VEGF targeting fluorescent tracer bevacizumab-IDRye800CW in breast cancer tissue, surrounding healthy tissue, tumor margins and lymph nodes. This is measured in surgical specimens after a single intravenous administration of 4,5 bevacizumab-IDRye800CW, using fluorescence microscopy and macroscopy techniques. Also the safety of bevacizumab-IDRye800CW is assessed. Another purpose is to assess the abilities of three different fluorescent signal detection systems to detect the fluorescent signal pre- and intra-operatively.
Trial Id: Cyberknife for Early Stage Breast Cancer Recruitment Status: Completed Trail description: This phase II study based on the Cyberknife Society study will evaluate the technical feasibility and acute toxicity of Partial Breast Irradiation (PBI) with the Cyberknife. It will evaluate quality of life (QOL) issues as they relate to treatment-related side effects, cosmetic result and patient convenience. It will evaluate outcome in terms of local control in the treated breast.

Radiosurgery is defined as the stereotactic delivery of ionizing radiation in 5 stages or less to a designated target with sub-millimeter accuracy. Radiosurgery in the context of this protocol will be given to the region of the tumor bed with 7 weeks of the lumpectomy and sent/axillary node sampling over the period of five to ten days using the Cyberknife (CK) or within the 7 weeks of the last chemotherapy treatment if given. Inclusion Criteria: Patients with stage 0, I, or II (Tis, Ti, or T2 <=3cm & NO) histologically confirmed invasive non-lobular carcinoma or ductal carcinoma in situ of the breast with a lesion <= 3 cm, treated with wide excision.
Negative inked histologic margins of excision or reexcision and clear of invasive tumor and DClS by at least 2mm
Negative post-excision or post-reexcision mammography if cancer presented with malignancy-associated microcalcifications; no remaining suspicious microcalcifications in the breast before radiotherapy.
No involved axillary lymph nodes by routine histologic examination (H&E) of sentinel node(s) or of nodes identified from axillary dissection.
Enrollment and initiation of CyberKnife therapy within 42 days of last breast cancer surgery or last chemotherapy treatment. Exclusion Criteria: Patients with invasive lobular carcinoma or nonepithelial breast malignancies such as sarcoma or lymphoma.
Patients with multicentric carcinoma or with other clinically or radiographically suspicious areas in the ipsilateral breast unless confirmed to be negative for malignancy by biopsy.
Patients who are pregnant.
Patients who have any histologically confirmed positive axillary nodes.
Patients with collagen vascular diseases, specifically systemic lupus erythematosis, scleroderma, or dermatomyositis with a creatine phosphokinase level above normal or with an active skin rash.
Provide inclusion criteria for trial id: NCT03946683  
 Patients with stage 0, I, or II (Tis, Ti, or T2 <=3cm & NO) histologically confirmed invasive non-lobular carcinoma or ductal carcinoma in situ of the breast with a lesion <= 3 cm, treated with wide excision.
Negative inked histologic margins of excision or reexcision and clear of invasive tumor and DClS by at least 2mm
Negative post-excision or post-reexcision mammography if cancer presented with malignancy-associated microcalcifications; no remaining suspicious microcalcifications in the breast before radiotherapy.
No involved axillary lymph nodes by routine histologic examination (H&E) of sentinel node(s) or of nodes identified from axillary dissection.
Enrollment and initiation of CyberKnife therapy within 42 days of last breast cancer surgery or last chemotherapy treatment.
Provide exclusion criteria for trial id: NCT03946683  
 Patients with invasive lobular carcinoma or nonepithelial breast malignancies such as sarcoma or lymphoma.
Patients with multicentric carcinoma or with other clinically or radiographically suspicious areas in the ipsilateral breast unless confirmed to be negative for malignancy by biopsy.
Patients who are pregnant.
Patients who have any histologically confirmed positive axillary nodes.
Patients with collagen vascular diseases, specifically systemic lupus erythematosis, scleroderma, or dermatomyositis with a creatine phosphokinase level above normal or with an active skin rash.